Yuan Cheng,Timothy Powers,Kate Ashton,James Brown,Scott Harried,Stephen A. Hitchcock,Ted Judd,Patricia Lopez,Thomas Nixey,Nick A. Paras,Steve F. Poon,David J. St. Jean, JR.,Qiufen Xue,Wenge Zhong
申请号：
US13511359
公开号：
US20120329830A1
申请日:
2010.11.19
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimers disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimers Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
